Table 4 Withdrawals and adverse events
|  |  |    Number of |    Percent with |  |  | ||
|---|---|---|---|---|---|---|---|
Outcome | Comparator |    Trials |    Patients | Ferric carboxymaltose |    Control | RB or RR 95% CI | NNTp 95% CI |
Withdrawals | Â | Â | Â | Â | Â | Â | Â |
All cause | All |    10 |    3835 |    6.4 |    7.5 |    0.8 (0.6 to 0.9) |    93 (37 to 180) |
|  | Oral iron |    6 |    1898 |    8.1 |    9.3 |    0.8 (0.6 to 1.03) |    not calculated |
Adverse event | All |    8 |    3319 |    1.0 |    1.6 |    0.6 (0.3 to 1.02) |    not calculated |
|  | Oral iron |    6 |    1898 |    1.5 |    1.9 |    0.7 (0.3 to 1.4) |    not calculated |
Lack of efficacy | All |    7 |    2967 |    0.6 |    0.8 |    0.8 (0.4 to 1.7) |    not calculated |
|  | Oral iron |    5 |    1546 |    1.1 |    1.2 |    0.8 (0.4 to 1.9) |    not calculated |
Adverse events | NNH 95% CI | ||||||
At least 1 AE | All |    8 |    2951 |    41 |    38 |    1.1 (1.0 to 1.2) |    not calculated |
|  | Oral iron |    5 |    1539 |    48 |    53 |    1.0 (0.9 to 1.1) |    not calculated |
Death | All |    10 |    3762 |    0.53 |    0.3 |    1.3 (0.5 to 3.4) |    not calculated |
|  | Oral iron |    6 |    1891 |    0.38 |    0.0 |    1.7 (0.4 to 6.6) |    not calculated |
Serious AE | All |    8 |    3303 |    2.5 |    2.3 |    1.0 (0.6 to 1.5) |    not calculated |
|  | Oral iron |    6 |    1891 |    3.1 |    2.3 |    1.3 (0.7 to 2.2) |    not calculated |
Hypotension | All |    6 |    2694 |    1.5 |    1.0 |    1.5 (0.8 to 2.7) |    not calculated |
|  | Oral iron |    4 |    1339 |    1.3 |    0.0 |    4.7 (1.1 to 21) |    79 (44 to 390) |